St John's wort for major depression

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Linde, Klaus ^a   Berner, Michael M ^b   Kriston, Levente ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

*Hypericum; *Phytotherapy; Adult; Antidepressive agents therapeutic use ; Depressive disorder *drug therapy ; Humans; Plant extracts *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

CALMIGEN; CITALOPRAM; D 0496; FELIS 650; FLUOXETINE; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MAPROTILINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STW3 V1; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; WS 5572; WS 5573;

BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HAMILTON SCALE; HUMAN; HYPERICUM PERFORATUM; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; QUALITY OF LIFE; REVIEW; SELF CONCEPT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77950251505     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Behnke 2002 {published data only} Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Advances in Therapy 2002;19:43-52.
2. Bjerkenstedt 2005 {published data only} Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression. A randomized, placebo-controlled multi-center study in outpatients. European Archives of Psychiatry and Clinical Neuroscience 2005;255: 40-7.
3. Bracher 2001 {published and unpublished data} Bracher A. Trial on HYP611 confirms effectiveness [HYP611-Studie bestätigt Wirksamkeit]. Ärztliche Praxis 2001;51 (suppl.):3-4.
4. Brenner 2000 {published data only} Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clinical Therapeutics 2000;22:411-9.
5. Brenner R, Madhusoodanan S, Pawlowska M. Efficacy of continuation treatment with hypericum perforatum in depression. Journal of Clinical Psychiatry 2002;63:455.
6. Fava 2005 {published data only} Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. Journal of Clinical Psychopharmacology 2005;25:441-7.
7. Gastpar 2005 {published and unpublished data} Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005;38: 78-87.
8. Gastpar 2006 {published and unpublished data} Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006; 39:66-75.
9. Harrer 1993 {published and unpublished data} Harrer G, Hübner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. Journal of Geriatric Psychiatry and Neurology 1994;7(suppl 1):S24-8.
10. Harrer G, Hübner WD, Podzuweit H. Wirksamkeit und Verträglichkeit des Hypericum-Präparates LI 160 im Vergleich mit Maprotilin. Nervenheilkunde 1993;12:297-301.
11. Harrer 1999 {published data only} Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittel-Forschung/Drug Research 1999;49:289-96.
12. HDTSG 2002 {published and unpublished data} * Hypericum Depression Trial Study Group. [Effect of Hypericum perforatum (St John's wort) in major depressive disorder. A randomized controlled trial]. JAMA 2002;287:1807-14.
13. Vitiello B, Shader RI, Parker CB, Ritz L, Harlan W, Greenblatt DJ, Gadde KM, Krishnan KRR, Davidson JRT. Hyperforim plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. Journal of Clin Psychopharmacology 2005;25:243-9.
14. Hänsgen 1996 {published and unpublished data} * Hängsen KD, Vesper J. Antidepressive Wirksamkeit eines hochdosierten Hypericum-Extraktes. Muenchener medizinische Wochenschrift 1996;138(3):29-33.
15. Hänsgen KD, Vesper J, Ploch M. Multizentrische Doppelblindstudie zur antidepressiven Wirksamkeit des Hypericumextraktes LI 160. Nervenheilkunde 1993;12:285-9.
16. Vesper J, Ploch M. Multi-center double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. Journal of Geriatric Psychiatry and Neurology 1994;7(suppl 1):S15-8.
17. Kalb 2001 {published data only} Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly depressed patients. Pharmacopsychiatry 2001;34:96-103.
18. Kasper 2006 {published and unpublished data} Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placeb-controlled, multi-center trial [ISRCTN77277298]. BMC Medicine 2006;4:14.
19. Laakmann 1998 {published data only} Laakmann G, Dienel A, Kieser M. Clinical significance of hyperforin for the efficacy of hypericum extracts on depressive disorders of different severities. Phytomedicine 1998;5:435-42.
20. Laakmann G, Schüle C, Baghai T, Kieser M. St John's wort in mild and moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998;31 (suppl):54-9.
21. Lecrubier 2002 {published and unpublished data} Lecrubier Y, Bech P. The Ham D6 is more homogeneous and as sensitive as the Ham D17. European Psychiatry 2007;22:252-5.
22. * Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. American Journal of Psychiatry 2002;159:1361-6.
23. Montgomery 2000 {published and unpublished data} Montgomery SA, Hübner WD, Grigoleit HG. Efficacy and tolerability of St. John's wort extract compared with placebo in patients with a mild to moderate depressive disorder. Phytomedicine 2000;7 (suppl II):107.
24. Moreno 2005 {published data only} Moreno RA, Teng CT, de Almeida KM, Tavares H jr. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Revista Brasileira de Psiquiatria 2005;28:29-32.
25. Philipp 1999 {published and unpublished data} Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicentre study of treatment for 8 weeks. BMJ 1999; 319:1534-9.
26. Schrader 1998 {published and unpublished data} Schrader E, Meier B, Brattström A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, mulitcentre study. Human Psychopharmacology 1998;13:163-9.
27. Schrader 2000 {published and unpublished data} Schrader E. Equivalence of St John's wort (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. International Clinical Psychopharmacology 2001;15:61-8.
28. Shelton 2001 {published and unpublished data} Gelenberg AJ, Shelton RC, Crits-Christoph P, Keller MB, Dunner DL, Hirschfeld RMA, Thase MAE, Russel JM, Lydiard RB, Gallop RJ, Todd L, Hellersteim DJ, Goodnick PJ, Keitner GI, Stahl SM, Halbreich U, Hopkins KS. The effectiveness of St. John's wort in major depressive disorder: a naturalistic phase 2 follow-up in which non-responders were provided alternate medication. Journal of Clinical Psychiatry 2004;65:1114-9.
29. * Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, et al. Effectiveness of St. John's wort in major depression. A randomized controlled trial. JAMA 2001;285:1978-86.
30. Szegedi 2005 {published and unpublished data} Anghelescu IG, Kohnen R, Szegedi A, Klement S, Kieser M. Comparison of hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Pharmacopsychiatry 2006;39:213-9.
31. * Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005;330:503-6.
32. Uebelhack 2004 {published and unpublished data} Uebelhack R, Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebocontrolled clinical trial. Advances in Therapy 2004;21:265-75.
33. van Gurp 2002 {published and unpublished data} van Gurp G, Meterissian GB, Haiek LN, McCusker J, Bellavance F. St John's wort or sertraline?Randomized controlled trial in primary care. Canadian Family Physician 2002;48:905-12.
34. Volz 2000 {published data only} Volz HP, Eberhardt R, Grilll G. Efficacy and tolerance of the St John's wort extract D-0496 in mild to moderate depression - a placebo-controlled, double-blind 6-week trial [Wirksamkeit und Verträglichkeit des Johanniskrautextraktes D-0496 bei leichten bis mittelschweren depressiven Episoden. Plazebokontrollierte Doppelblindstudie über 6 Wochen]. Nervenheilkunde 2000;19: 401-5.
35. Vorbach 1997 {published and unpublished data} Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997;30(suppl.2):81-5.
36. Wheatley 1997 {published and unpublished data} Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 1997;30 (suppl.2):77-80.
37. Witte 1995 {published and unpublished data} Witte B, Harrer G, Kaptan T, Podzuweit H, Schmidt U. Behandlung depressiver Verstimmungen mit einem hochkonzentrierten Hypericumpräparat - eine multizentrische plazebokontrollierte Doppelblindstudie. Fortschritte der Medizin 1995;113:404-8.
38. Woelk 2000 {published data only} Woelk H for the Remotiv/Imipramine Study Group. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 2000;321:536-9.
39. Agrawal 1994 {published data only} Agrawal A, Dixit SP, Dubey GP, Gupta BS. Clinical evaluation of anti-depressant properties of basant (hypericum perforatum). Pharmacopsychoecologia 1994;7:253-6.
40. Albertini 1986 {published data only} Albertini H. Evaluation d'un traitement homeopathique de la nevralgie dentaire. In: Boiron J, Belon P, Hariveau E editor(s). Recherche en homeopathie. Lyon: Fondation francaise pour la recheche en homeopathie, 1986:75-7.
41. Bendre 1980 {published data only} Bendre VV, Dharmadhikari SD. Arnica montana and hypericum in dental practice. Hahnemann Gleanings 1980;47:70-2.
42. Bergmann 1993 {published and unpublished data} Bergmann R, Nübner J, Demling J. Behandlung leichter bis mittelschwerer Depressionen. Therapiewoche Neurol Psychiatr 1993; 7:235-40.
43. Bernhadt 1993 {published data only} Bernhardt M, Liske E, Ebeling L. Hypericum perforatum in der Therapie leichter bis mittelschwerer Depressionen: Vergleich der antidepressiven Wirksamkeit von zwei unterschiedlichen Dosierungsschemata. Bonn, 5. Phytotherapie-Kongreß 1993.
44. Brockmöller 1997 {published data only} Brockmöller J, Reum T, Bauer S, Kerb R, Hübner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30(suppl.2): 94-101.
45. Czekalla 1997 {published data only} Czekalla J, Gastpar M, Hübner WD, Jäger D. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopschychiatry 1997;30(supp.2):86-8.
46. Dittmer 1992 {published data only} Dittmer TLJ. Die Behandlung von psychovegetativen Störungen mit Johanniskraut-Öl (Jukunda-Rot-Öl-Kapseln). Naturheilpraxis mit Naturmedizin 1992;45:118-22.
47. Ditzler 1992 {published and unpublished data} Ditzler K, Gessner B, Schatton WFH, Willems M. Clinical trial on Neuropas versus placebo in patients with mild to moderate depressive symptoms: a placebo-controlled, randomised double-blind study. Complementary Therapies in Medicine 1994;2:5-13.
48. Ditzler K, Schatton W. Johanniskraut bei leichten bis mittelschweren Depressionen - Ergebnisse einer plazebo-kontrollierten Doppelblindstudie. Heilkunst 1992;104:263-70.
49. Gu 2001 {published data only} Gu N, Li H, Shu L. Zhang H, Weng Z, Ma C, Wang M. Multicenter study of St John's wort extract in treatment of mild to moderate depression. Chinese Journal of Clinical Pharmacy 2001; 10:271-4.
50. Halama 1991 {published and unpublished data} Halama P. Wirksamkeit des Hypericum-Extraktes LI 160 bei 50 Patienten einer psychiatrischen Fachpraxis. Nervenheilkunde 1991; 10:305-7.
51. Halama P. Wirksamkeit des Johanniskrautextraktes LI 160 bei depressiver Verstimmung. Nervenheilkunde 1991;10:250-3.
52. Harrer 1991 {published and unpublished data} Harrer G, Schmidt U, Kuhn U. "Alternative" Depressionsbehandlung mit einem Hypericum-Extrakt. Therapiewoche Neurologie 1991;5:710-6.
53. Herberg 1992 {published data only} Herberg KW. Psychotrope Phytopharmaka im Test - Alternative zu synthetischen Psychopharmaka. Therapiewoche 1992;44:704-13.
54. Hoffmann 1979 {published data only} Hoffmann J, Kühl ED. Therapie von depressiven Zuständen mit Hypericin. Zeitschrift für Allgemeinmedizin 1979;55:776-82.
55. Hottenrott 1997 {published data only} Hottenrott K, Sommer HM, Lehrl S, Hauer H. Der Einfluss von Vitamin E und Johanniskraut- Trockenextrakt auf die Ausdauerleistungsfähigkeit von Wettkampfsportlern. Eine placebo-kontrollierte Doppelblindstudie mit Langstreckenläufern und Triathleten. Deutsche Zeitschrift für Sportmedizin 1997;48:22-7.
56. Häring 1996 {published and unpublished data} Häring B, Hauns B, Hermann C, Hübner WD, Maier-Lenz H, Marschner N. A double-blind, placebo-controlled pilot study of LI 160 in combination with chemotherapy in patients with solid tumors. Abstracts of the 2nd International Congress on Phytomedicine. Munich, 1996:SL-88.
57. Hübner 1993 {published and unpublished data} Hübner WD, Lande S, Podzuweit H. Behandlung larvierter Depressionen mit Johanniskraut. Nervenheilkunde 1993;12: 278-280.
58. Hübner WD, Lande S, Podzuweit H. Hypericum treatment of mild depression with somatic symptoms. Journal of Geriatric Psychiatry and Neurology 1994;7(suppl 1):S12-5.
59. Johnson 1992 {published data only} Johnson D. Neurophysiologische Wirkungen von Hypericum im Doppelblindversuch mit Probanden. Nervenheilkunde 1991;10: 316-7.
60. * Johnson D, Siebenhüner G, Hofer E, Sauerwein-Giese E, Frauendorf A. Einfluß von Johanniskraut auf die ZNS-Aktivität. Neurologie und Psychiatrie 1992;6:436-44.
61. Johnson 1993 {published data only} Johnson D, Ksciuk H, Woelk H, Sauerwein-Giese E, Frauendorf A. Effetcs of hypericum extract LI 160 compared with maprotiline on resting EEG and evoked potentials in 24 volunteers. Journal of Geriatric Psychiatry and Neurology 1994;7(suppl 1):S44-6.
62. Johnson D, Ksciuk H, Woelk H, Sauerwein-Giese E, Frauendorf A. Wirkungen mit Johanniskraut-Extrakt LI 160 im Vergleich mit Maprotilin auf Ruhe-EEG und evozierte Potentiale bei 24 Probanden. Nervenheilkunde 1993;12:328-30.
63. Kniebel 1988 {published and unpublished data} Hiller KO, Rahlfs V. Therapeutische Äquivalenz eines hochdosierten Phytopharmakons mit Amitriptylin bei ängstlich-depressiven Verstimmungen - Reanalyse einer randomisierten Studie unter besonderer Beachtung biometrischer und klinischer Aspekte. Forschende Komplementärmedizin 1995;2:123-32.
64. * Kniebel R, Burchard JM. Zur Therapie depressiver Verstimmungen in der Praxis. Zeitschrift für Allgemeinmedizin 1988;64:689-96.
65. Kugler 1990a {published data only} Kugler J, Weidenhammer W, Schmidt A, Groll S. [Therapie depressiver Zustände. Hypericum-Extrakt Steigerwald als Alternative zur Benzodiazepin-Behandlung]. Zeitschrift für Allgemeinmedizin 1990;66 (suppl 1):21-9.
66. Kugler 1990b {published data only} Kugler J, Schmidt A, Groll S, Weidenhammer W. Zur Pharmakodynamik eines Hypericum-Extraktes. Untersuchungen bei Patienten mit depressiven Zuständen im Vergleich zu Bromazepam und Placebo. Zeitschrift für Allgemeinmedizin 1990; 66(suppl.):13-20.
67. König 1993 {published data only} König CD. Hypericum perforatum L. (gemeines Johanniskraut) als Therapeutikum bei depressiven Verstimmungszuständen - eine Alternative zu synthetischen Arzneimitteln. University of Basel: Thesis, 1993.
68. Lehrl 1993 {published and unpublished data} * Lehrl S, Woelk H. Ergebnisse von Messungen der kognitiven Leistungsfähigkeit bei Patienten unter der Therapie mit Johanniskraut. Nervenheilkunde 1993;12:281-4.
69. Lehrl S, Woelk H. Psychometrische Messung der Leistungkapazität unter antidepressiver Therapie mit Johanniskraut. Nervenheilkunde 1991;10:313-5.
70. Lenoir 1999 {published data only} Lenoir S, Degenring FH, Saller R. A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of hypericum perforatum L. Phytomedicine 1999;6:141-6.
71. Li 2005 {published data only} Li YM, Li GY, Wang XL, & Yu LF. Rehabilitation effect of Saint John's Wort extract on depression and myocardial function after coronary artery bypass grafting: A randomized grouping, placebo-control and blind evaluation. Chinese Journal of Clinical Rehabilitation 2005;9(28):38-9.
72. Maisenbacher 1995 {published data only} Maisenbacher J, Schmidt U, Schenk N. Therapie mit Hypericum bei Angstzuständen. Therapiewoche Neurologie Psychiatrie 1995;9: 65-60.
73. Martinez 1993 {published data only} Kasper S. Treatment of seasonal affective disorder (SAD) with hypericum extract. Pharmacopsychiatry 1997;30(suppl.2):89-93.
74. Martinez B, Kasper S, Ruhrmann B, Möller HJ. Hypericum in der Behandlung von saisonal abhängigen Depressionen. Nervenheilkunde 1993;12:302-7.
75. Martinez B, Kasper S, Ruhrmann B, Möller HJ. Hypericum in the treatment of seasonal affective disorders. Journal of Geriatric Psychiatry and Neurology 1994;7(suppl 1):S29-33.
76. Mo 2004 {published data only} Mo WY, Yu HY, Yang Y. Comparison of Saint John' Wort extract with fluoxetine in the treatment of post-stroke depression. Chinese Journal of New Drugs 2004;13:942- 4.
77. Osterheider 1992 {published and unpublished data} Osterheider M, Schmidtke A, Beckmann H. Behandlung depressiver Syndrome mit Hypericum (Johanniskraut - eine placebokontrollierte Doppelblindstudie. Fortschritte Neurologie Psychiatrie 1992;60(suppl.2):210-1.
78. Panijel 1985 {published data only} Panijel J. Die Behandlung mittelschwerer Angstzustände. Therapiewoche 1985;41:4659-68.
79. Quandt 1993 {published and unpublished data} Quandt J, Schmidt U, Schenk N. Ambulante Behandlung leichter und mittelschwerer depressiver Verstimmungen. Der Allgemeinarzt 1993;15(2):97-102.
80. Reh 1992 {published and unpublished data} Reh C, Laux P, Schenk N. Hypericum-Extrakt bei Depressionen - eine wirksame Alternative. Therapiewoche 1992;42:1576-81.
81. Schlich 1987 {published and unpublished data} Schlich D, Braukmann F, Schenk N. Behandlung depressiver Zustände mit Hypericinium. Psycho 1987;13:440-7.
82. Schmidt 1989 {published and unpublished data} Schmidt U, Schenk N, Schwarz I, Vorberg G. Zur Therapie depressiver Verstimmungen. Psycho 1989;15:665-71.
83. Schmidt 1993 {published and unpublished data} Schmidt U. Konstantes Reaktionsvermögen unter antidepressiver Theerapie mit dem Hypericum-Präparat LI 160. Nervenheilkunde 1991;10:311-2.
84. * Schmidt U, Sommer H. Johanniskraut-Extrakt zur ambulanten Therapie der Depression. Fortschritte der Medizin 1993;111: 339-42.
85. Schmidt 1993b {published data only} Schmidt U, Harrer G, Kuhn U, Berger-Deinert W, Luther D. Wechselwirkungen von Hypericin-Extrakt mit Alkohol. Nervenheilkunde 1993;12:314-9.
86. Schulz 1993 {published data only} Schulz H, Jobert M. Der Einfluß von Johanniskraut auf das Schlaf-EEG bei älteren Probandinnen. Nervenheilkunde 1993;12:323-7.
87. Schulz H, Jobert M. Effetcs of hypericum extract on the sleep EEG in older volunteers. Journal of Geriatric Psychiatry and Neurology 1994;7(suppl 1):S39-43.
88. Sindrup 2000 {published data only} Sindrup SS, Madsen C, Bach FW, Gram LF, Jensen TS. [St. John's wort has no effect on pain in polyneuropathy]. Pain 2000;91: 361-365.
89. Sommer 1994 {published and unpublished data} Harrer G, Sommer H. Therapie leichter/mittelschwerer Depressionen mit Hypericum. Münchener medizinische Wochenschrift 1993;135:305-9.
90. Harrer G, Sommer H. Treatment of mild/moderate depressions with Hypericum. Phytomedicine 1994;1:3-8.
91. Sommer H. Besserung psychovegetativer Beschwerden durch Hypericum im Rahmen einer multizentrischen Dopppelblindstudie. Nervenheilkunde 1991;10:308-10.
92. Sommer H, Harrer G. Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients. Journal of Geriatric Psychiatry and Neurology 1994;7(suppl 1):S9-11.
93. Sommer H, Harrer G. Placebo-kontrollierte Studie zur Wirksamkeit eine Hypericumpräparates bei 105 Patienten mit Depressionen. Nervenheilkunde 1993;12:274-7.
94. Spielberger 1985 {published data only} Spielberger E. Johanniskraut-Präparat lindert selbst mittelschwere Depressionen. Ärztliche Praxis 1985;37:2546-7.
95. Staffeldt 1993 {published data only} Staffeldt B, Kerb R, Brockmöller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. Journal of Geriatric Psychiatry and Neurology 1994;7 (suppl 1):S47-53.
96. Staffeldt B, Kerb R, Brockmöller J, Ploch M, Roots I. Pharmakokinetik von Hypericin und Pseudohypericin nach oraler Einnahme des Johanniskraut-Extrakts LI 160 bei gesunden Probanden. Nervenheilkunde 1993;12:331-8.
97. Steger 1985 {published and unpublished data} Steger W. Depressive Verstimmungen. Zeitschrift für Allgemeinmedizin 1985;61:914-8.
98. Volz 2002 {published data only} Volz HP, Murck H, Kasper S, Möller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology 2002;164:294-300.
99. Vorbach 1994 {published and unpublished data} Vorbach EU, Hübner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study in 135 outpatients. Journal of Geriatric Psychiatry and Neurology 1994;7(suppl 1): S19-23.
100. Vorbach EU, Hübner WD, Arnoldt KH. Wirksamkeit und Verträglichkeit des Hypericum-Extraktes LI 160 im Vergleich mit Imipramin. Nervenheilkunde 1993;12:290-6.
101. Warnecke 1986 {published data only} Warnecke G. Beeinflussung klimakterischer Depressionen. Zeitschrift für Allgemeinmedizin 1986;62:1111-3.
102. Werth 1989 {published data only} Werth W. Psychotonin M versus Imipramin in der Chirurgie. Der Kassenarzt 1989;15:64-8.
103. Wienert 1991 {published data only} Wienert V, Classen R, Hiller KO. Zur Frage der Photosensibilisierung von Hypericin in einer Baldrian-Johanniskraut-Kombination - klinisch-experimentelle, plazebokontrollierte Vergleichsstudie. Lübeck-Travemünde, 3rd Phytotherapy Congress 1991.
104. Winkel 2000 {published data only} * Winkel R, Koritsch HD, Piayda H, Trenckmann. [Phytopharmakotherapie der komorbiden depressiven Störungen bei Alkoholabhängigkeit - Wirksamkeit des Johanniskrautextraktes LI 160 bei komorbid-depressiv Alkoholerkrankten]. In: Trenckmann U editor(s). Phytopharmaka und seelische Störungen. Neu-Isenburg: Lingua Med, 2000:43-51.
105. Winkel R, Koritsch HD, Piayda H, Trenckmann U. St. John's wort extract LI 160 in depressive, alcohol addicted patients. Phytomedicine 2000;7 (suppl II):19.
106. Zeller 2000 {published data only} Zeller K. [Once daily administration of hypericum extract (STW 3): a convenient treatment]. In: Chrubasik S, Roufogalis BD editor(s). Herbal medicinal products for the treatment of pain. Lismore: Southern Cross University Press, 2000:164-8.
107. Caccia 2005 Caccia S. Anti-depressant-like components of hypericum perforatum extracts: an overview of their pharmacokinetics and metabolism. Current Drug Metabolism 2005;6:531-43.
108. Candy 2008 M Candy B, Jones L, Williams R, Tookman A, King. Psychostimulants for depression. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006722.pub2]
109. CGI 1970 National Institutes of Mental Health. CGI - Clinical Global Impressions. In: Guy W editor(s). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1970:217-222.
110. Deeks 2006 Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Analysing and presenting results. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester: John Wiley & Sons, Ltd, 2006.
111. DSM-IV-TR American Psychiatric Association. DSM-IV-TR® . http://www.dsmivtr.org/index.cfm.
112. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder CE. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315: 629-34.
113. Ernst 1995 Ernst E. St. John's wort, an anti-depressant?A systematic, criteria-based review. Phytomedicine 1995;2:67-71.
114. Ernst 1999 Ernst E. Second thoughts about safety of St John's wort. Lancet 1999;354:2014-5.
115. Gaster 2000 Gaster B. St John's wort for depression. A systematic review. Archives of Internal Medicine 2000;160:152-6.
116. Hamilton 1960 Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
117. Hammerness 2003 Hammerness P, Basch E, Ulbricht C. St. John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003;44:271-82.
118. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
119. Higgins 2008 Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
120. Härter 2003 Härter M, Bermejo I, Schneider F, Katz S, Gaebel W, Hegerl U, Niebling W, Berger M. Clinical practice guideline for the diagnosis and treatment of depressive disorders in primary care [Versorgungsleitlinien zur Diagnostik und Therapie depressiver Störungen in der hausärztlichen Praxis]. Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 2003;7 (suppl. IV):16-35.
121. ICD-10 World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007. http://www.who.int/classifications/apps/icd/icd10online/.
122. ICSI 2007 Institute for Clinical Systems Improvement (ICSI). Health care guideline: major depression in adults in primary care. www.icsi.org 2007.
123. Jadad 1996 Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
124. Khan 2000 Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Archives of General Psychiatry 2000;57:311-7.
125. Kim 1999 Kim HL, Streltzer J, Goebert D. St John's wort for depression: a meta-analysis of well-defined clinical trials. Journal of Nerval and Mental Diseases 1999;187:532-9.
126. Kirsch 2002 Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The emporor's new drugs: an analysis of antidepressant medication submitted to the U.S. Food and Drug Administration. Prevention & Treatment 2002; 5:article 23.
127. Kirsch 2008 Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine 2008;5:260-8.
128. Knüppel 2004 Knüppel L, Linde K. Adverse effects of St. John's wort - a systematic review. Journal of Clinical Psychiatry 2004;65:1470-9.
129. Linde 1996 Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta-analysis of randomized clinical trials. BMJ 1996;313:253-8.
130. Linde 1996b Linde K, Worku F, Melchart D, Wiesner-Zechmeister M, Pothmann R, Weinschütz T, Melchart D. Randomized clinical trials of acupuncture for asthma - a systematic review. Forschende Komplementä rmedizin 1996;3:148-55.
131. Linde 1997 Linde K, Clausisus N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB. Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet 1997;350: 834-43.
132. Lipsey 2000 Lipsey M, Wilson DB. Practical meta-analysis. Applied social research methods series, Vol. 49. London: Sage Publications, 2000.
133. Montgomery 1979 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
134. Murck 2002 Murck H. Atypical depression and related disorders - neurobiological basis for their treatment with St. John's wort [Die atypische Depression und verwandte Erkrankungen - neurobiologische Grundlagen für ihre Behandlung mit Johanniskraut-Extrakt]. Wiener medizinische Wochenschrift 2002; 152:398-403.
135. Murck 2005 Murck H, Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Mannel M, Rosenbaum JF. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. International Journal of Neuropsychopharmacology 2005;8:215-21.
136. Nahrstedt 1997 Nahrstedt A, Butterweck V. Biologically active and other chemical constitutents of the herb hypericum perforatum L. Pharmacopsychiatry 1997;30(suppl 2):129-34.
137. Nieuwstraten 2006 Nieuwstraten C, Labiris NR, Holbrock A. Systematic overview of drug interactions with antidepressant medications. Canadian Journal of Psychiatry 2006;51:300-16.
138. Posternak 2007 Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant effiacy trials. British Journal of Psychiatry 2007;190: 287-92.
139. Reichling 2003 Reichling J, Hostanska K, Saller R. St. John's wort (Hypericum perforatum L.) - multicompound preparations versus single substances [Johanniskraut (Hypericum perforatum L.) - Vielstoffgemische kontra phytogene Einzelstoffe]. Forschende Komplementärmedizin und Klassische Naturheilkunde 2003;10 (suppl 1):28-32.
140. Smith 2004 Smith L, Ernst E, Ewings P, Myers P, Smith C. Co-ingestion of herbal medicines and warfarin. British Journal of General Practice 2004;54:439-41.
141. Sterne 2001 Sterne JA, Egger M, Davey Smith G. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101-5.
142. Thompson 1999 Thompson SD, Sharp SJ. Explaining heterogeneity in meta-analyses: a comparison of methods. Statitics in Medicine
143. Turner 2008 Turner EH, Matthews MM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008;358: 252-60.
144. Ustun 2004 Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murrary CJ. Global burden of depressive disorders in the year 2000. British Journal of Psychiatry 2004;184:386-92.
145. Volz 1997 Volz HP. Controlled clinical trials of hypericum extract in depressed patients - an overview. Pharmacopsychiatry 1997;30(suppl 2):72-6.
146. von Zerssen 1996 von Zerssen D. D-S. In: AMDP, CIPS editor(s). Rating scales for psychiatry. Weinheim: Beltz Test, 1990:section 2.8.
147. Wheatley 1998 Wheatley D. Hypericum extract - potential in the treatment of depression. CNS Drugs 1998;9:431-440.
148. Whitten 2006 Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. British Journal of Clinical Pharmacology 2006;62:512-26.
149. Williams 2000 Williams JW jr, Mulrow CD, Chiquette E, Hitchcock NP, Aguilar C, Cornell J. A systmatic review of newer pharmacotherapies for depression in adults: evidence report summary. Annals of Internal Medicine 2000;132:743-56.
150. Wilson 2002 Wilson DB. SPSS, Stata, and SAS macros for performing meta-analytic analyses. http://mason.gmu.edu/~dwilsonb/ma.html. last uptated: 15-1-2002. accessed: 10-11-2003.
151. Wurglics 2003 Wurglics M, Schulte-Löbbert S, Dingermann T, Schubert-Zsilavecs M. Rational and traditional hypericum preparations [Rationale und traditionelle Johanniskraut-Präparate]. Deutsche Apotheker Zeitung 2003;143:1454-8.
152. Wurglics 2006 Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a "modern" herbal antidepresant: pharmacokinetics of active ingredients. Clinical Pharmacokinetics 2006;45:449-68.
153. Linde 1998 Linde K, Mulrow CD. St John's wort for depression. Cochrane Database of Systematic Reviews 1998, Issue 4.
154. Linde 2005a Linde K, Mulrow CD, Berner M, Egger M. St John's wort for depression. Cochrane Database of Systematic Reviews 2005, Issue 2.
155. Linde 2005b Linde K, Berner M, Egger M, Culrow C. St John's wort for depression - meta-analysis of randomised controlled trials. British Journal of Psychiatry 2005;186:99-107.